

Ipilimumab

Cat. No.:	HY-P9901
CAS No.:	477202-00-9
Molecular Weight:	145313.36
Target:	CTLA-4
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ipilimumab is a fully human monoclonal IgG1k antibody against the cytotoxic T-lymphocyte antigen-4 (CTLA-4), an immune-inhibitory molecule expressed in activated T cells and in suppressor T regulatory cells.
In Vitro	Ipilimumab inhibits CTLA-4, allowing the T cell immune response to be reactivated against tumor cells. Ipilimumab can promote antitumor activity as a single agent or in combination with cytokines, chemotherapy, or vaccines ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Patent. US20200261591A1

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Movva S, et al. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. Expert Opin Biol Ther. 2009 Feb;9(2):231-41.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA